SGS ISL Expands Capabilities with Polarised Light Microscopy for Asbestos Testing

Pharmaceutical manufacturers face increasing scrutiny to ensure raw materials are free from asbestos contamination. With evolving pharmacopoeial standards, companies need reliable partners who can deliver robust testing methods to support compliance and safeguard supply. SGS ISL is expanding its capabilities to meet this need.

From December 2025, SGS ISL will introduce Polarised Light Microscopy (PLM) to complement its existing X-ray powder diffraction (XRPD) services for asbestos testing in raw materials. This dual capability provides a more comprehensive approach, offering clients accurate results and stronger quality assurance when navigating complex regulatory expectations.

Global regulators are placing greater emphasis on asbestos detection, making the use of multiple analytical techniques increasingly valuable.

By integrating PLM with XRPD, SGS ISL enables clients to reduce the risk of non-compliance, protect production pipelines and demonstrate due diligence in regulatory submissions. This combined approach ensures that manufacturers can maintain supply continuity while meeting heightened industry standards.

The investment reflects SGS ISL’s commitment to supporting clients with evolving regulatory demands. As quality control expectations rise across the sector, SGS ISL continues to strengthen its analytical infrastructure to provide reliable, compliant and efficient testing solutions.

Explore the full range of analytical capabilities with SGS ISL: Quality Control Release Testing for Pharmaceutical Products | SGS